Fintel reports that on April 1, 2025, William Blair upgraded their outlook for Nayax (NasdaqGS:NYAX) from Market Perform to ...

William Blair reissued their market perform rating on shares of FibroGen (NASDAQ:FGEN – Free Report) in a research report ...

Equities researchers at William Blair issued their FY2028 earnings estimates for Tempest Therapeutics in a research report ...

Palantir is poised to win a U.S. Army contract that could eventually deliver annual recurring revenue approaching $100 million, said a William Blair analyst.

William Blair analyst Margaret Kaczor maintained a Hold rating on Neuronetics (STIM – Research Report) today. The company’s shares closed ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

In a report released today, Ryan Merkel from William Blair maintained a Buy rating on Acuity Brands (AYI – Research Report). The company’s ...

Already reeling from years of market chaos, the announced departure of CBER chief Peter Marks sent a ripple across biopharma ...

Much of the attention this week for markets and economists will center on the rollout of President Donald Trump’s tariffs.

Tesla shares fell more than 5% on Wednesday, ending the EV maker's blistering rebound out of a prolonged slump.

Shares of major US drugmakers plunged Monday after reports surfaced that the FDA’s leading vaccine official was forced out as part of a shakeup at federal health agencies ordered by the ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...